Page 11 - norgine-annual-report-2016

Priority 1: MACROGOL 3350, SODIUM BICARBONATE,
SODIUM CHLORIDE, POTASSIUM CHLORIDE
Achieve double digit growth MOVICOL maintained its leading position in Europe, generating more
®
than €159 million in sales, despite generic competition (2015: €159
million). Although MOVICOL was launched 20 years ago it continues
®
to be the market leader in Europe in its class. Norgine remains focused
on providing a product that is trusted by patients and prescribers.

Norgine launched a new MOVICOL formulation, MOVICOL Ready to
®
®
Growing Norgine’s core products – MOVICOL , MOVIPREP and Take (macrogol 3350, sodium hydrogen carbonate, sodium carbonate,
®
®
XIFAXAN , and raising the profile and reach of its other products is potassium chloride) that offers patients a discrete and convenient way
®
®
central to delivering on Norgine’s goal to achieve double digit growth. to take their laxative. MOVICOL Ready to Take is a ready mixed,
While total sales growth, net of divestments, was short of the long pocket size dose that can be easily incorporated into daily life. The Norgine progressed with the launch of
®
term target of sustained double digit growth, the progress made with product was launched in Germany and the UK. ENDOCUFF VISION to ensure its availability
Norgine’s newer products sets the stage for attaining this objective in all of Norgine’s markets – Australia and
New Zealand, Austria, Belgium, Finland,
in 2020.
France, Denmark, Germany, Italy, Ireland,
Netherlands, New Zealand, Norway, Portugal,
®
Product Sales (€million) Norgine’s second largest product, MOVIPREP generated sales Spain, Sweden, Switzerland and the UK.
in 2016 of €53.5 million, a 5% growth over 2015 (€51 million).
Growth
Product Indication 2015 2016 The use of improved visualisation techniques
®
in 2016 MOVIPREP is currently available in Europe and Australia through
®
Norgine’s own infrastructure and in the US, India, Japan, Russia using devices such as ENDOCUFF VISION
Maximise the MOVICOL ® Constipation 159 159 0% is fundamental to help improve colorectal
growth of our and Canada via partners.
core products MOVIPREP ® Bowel preparation 51 54 5% cancer detection as it enables better detection
of adenomas and polyps that ultimately
Travellers diarrhoea will improve patients’ outcomes and save
XIFAXAN ® and hepatic 34 41 21%
encephalopathy healthcare systems resources.
XIFAXAN continued to be the key growth driver, with sales of
®
ENDOCUFF VISION is a single-use
®
€41.3 million in 2016, an increase of 21% (2015: €34 million).
On a like-for-like basis at constant endoscopic overtube which fits onto the
distal end of an endoscope.
®
exchange rates, underlying revenue XIFAXAN 550 is now reimbursed in most Norgine territories. In 2016,
growth was 6.8%. it was granted reimbursement status by the Ministry of Health in the
In 2015, Norgine acquired 70% of Arc
Netherlands, Ministry van Volksgezondheid, Welzijn en Sport, when
Medical Design Ltd, the developer of
added to lactulose, for prophylaxis of the 3rd and following episodes
ENDOCUFF VISION .
®
of overt hepatic encephalopathy in patients ≥ 18 years.
Recent data, the IMPRESS study, further demonstrated the value
that XIFAXAN 550mg can bring to patients suffering from hepatic
®
encephalopathy and to healthcare systems overall. The study showed
that XIFAXAN 550mg reduces the recurrence of episodes of hepatic
®
encephalopathy, therefore decreasing the number of hospitalisations
for patients. This in turn means lower costs for hospital admissions
and bed occupancy.

9 10